FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4235302521> ?p ?o ?g. }

• W4235302521 endingPage "523" @default.
• W4235302521 startingPage "518" @default.
• W4235302521 abstract "Patients with resistant hypertension (RH) have a high risk of developing cardiovascular events; therefore, new therapeutic approaches to better control blood pressure may be useful in improving cardiovascular outcomes. The prevalence of obstructive sleep apnea (OSA) is very high among patients with RH. Continuous positive airway pressure (CPAP) has been shown to be an effective treatment for reducing blood pressure in patients with RH. Nevertheless, the long-term effect of CPAP treatment on cardiovascular outcomes has not been explored. The main objective of the SARAH study is to assess the impact of OSA and its treatment on cardiovascular outcomes (morbidity and mortality) in patients with RH. This study is a multi-center, prospective, observational cohort study. A total of 1371 patients with RH will be enrolled in the study and followed once a year for five years. At inclusion, ambulatory blood pressure monitoring (ABPM) and a sleep study will be performed in all subjects. Socio-demographic, clinical and cardiovascular variables will be collected at baseline and follow-up. Subsequently, subjects with OSA will be managed according to local standard practice. Based on the OSA diagnosis and its treatment, three cohorts of subjects with RH will be defined: non-OSA, treated OSA and non-treated OSA. This study will contribute to elucidating the long-term impact of OSA treatments on blood pressure control and cardiovascular outcomes in patients with RH. These results will contribute to improve the cardiovascular prognosis of patients with RH. Los pacientes con hipertensión resistente (HR) tienen un elevado riesgo de desarrollar eventos cardiovasculares; así, las nuevas estrategias terapéuticas para el control de la presión arterial podrían ser útiles para mejorar los resultados cardiovasculares. La prevalencia de la apnea obstructiva del sueño (AOS) es muy elevada entre los pacientes con HR. Se ha demostrado que la presión positiva continua en la vía aérea (CPAP) constituye un tratamiento efectivo para reducir la presión arterial en pacientes con HR. Sin embargo, todavía no se han estudiado los efectos a largo plazo del tratamiento con CPAP sobre los resultados cardiovasculares. El principal objetivo del estudio SARAH es evaluar el impacto de la AOS y su tratamiento en los resultados cardiovasculares (morbilidad y mortalidad) en pacientes con HR. Este es un estudio observacional prospectivo multicéntrico en el que se incluirán 1.371 pacientes con HR, a los cuales se les realizará seguimiento una vez al año durante 5 años. En el momento de la inclusión se realizará a todos los pacientes monitorización ambulatoria de la presión arterial (MAPA), así como un estudio de sueño. Se recogerán las variables sociodemográficas, clínicas y cardiovasculares tanto al inicio del estudio como durante el seguimiento. Posteriormente, los individuos con AOS serán tratados de acuerdo con la práctica clínica estándar de cada centro. Se definirán 3 grupos en función del diagnóstico de AOS y su tratamiento: sin AOS, con AOS en tratamiento, con AOS sin tratar. Este estudio contribuirá a averiguar el impacto a largo plazo del tratamiento de la AOS en el control de la presión arterial y los resultados cardiovasculares en pacientes con HR. Asimismo, estos resultados contribuirán a mejorar el pronóstico cardiovascular de los pacientes con HR." @default.
• W4235302521 created "2022-05-12" @default.
• W4235302521 creator A5001055180 @default.
• W4235302521 creator A5012466949 @default.
• W4235302521 creator A5016043840 @default.
• W4235302521 creator A5018868775 @default.
• W4235302521 creator A5022338982 @default.
• W4235302521 creator A5029438535 @default.
• W4235302521 creator A5032013233 @default.
• W4235302521 creator A5040059941 @default.
• W4235302521 creator A5044423405 @default.
• W4235302521 creator A5046990649 @default.
• W4235302521 creator A5057743372 @default.
• W4235302521 creator A5060011101 @default.
• W4235302521 creator A5074351899 @default.
• W4235302521 creator A5077648295 @default.
• W4235302521 creator A5078491071 @default.
• W4235302521 creator A5084391674 @default.
• W4235302521 date "2018-10-01" @default.
• W4235302521 modified "2023-10-18" @default.
• W4235302521 title "Rationale and Methodology of the SARAH Trial: Long-Term Cardiovascular Outcomes in Patients With Resistant Hypertension and Obstructive Sleep Apnea" @default.
• W4235302521 doi "https://doi.org/10.1016/j.arbr.2018.03.003" @default.
• W4235302521 hasPublicationYear "2018" @default.
• W4235302521 type Work @default.
• W4235302521 citedByCount "0" @default.
• W4235302521 crossrefType "journal-article" @default.
• W4235302521 hasAuthorship W4235302521A5001055180 @default.
• W4235302521 hasAuthorship W4235302521A5012466949 @default.
• W4235302521 hasAuthorship W4235302521A5016043840 @default.
• W4235302521 hasAuthorship W4235302521A5018868775 @default.
• W4235302521 hasAuthorship W4235302521A5022338982 @default.
• W4235302521 hasAuthorship W4235302521A5029438535 @default.
• W4235302521 hasAuthorship W4235302521A5032013233 @default.
• W4235302521 hasAuthorship W4235302521A5040059941 @default.
• W4235302521 hasAuthorship W4235302521A5044423405 @default.
• W4235302521 hasAuthorship W4235302521A5046990649 @default.
• W4235302521 hasAuthorship W4235302521A5057743372 @default.
• W4235302521 hasAuthorship W4235302521A5060011101 @default.
• W4235302521 hasAuthorship W4235302521A5074351899 @default.
• W4235302521 hasAuthorship W4235302521A5077648295 @default.
• W4235302521 hasAuthorship W4235302521A5078491071 @default.
• W4235302521 hasAuthorship W4235302521A5084391674 @default.
• W4235302521 hasConcept C126322002 @default.
• W4235302521 hasConcept C149323552 @default.
• W4235302521 hasConcept C164705383 @default.
• W4235302521 hasConcept C177713679 @default.
• W4235302521 hasConcept C201903717 @default.
• W4235302521 hasConcept C23131810 @default.
• W4235302521 hasConcept C2776006263 @default.
• W4235302521 hasConcept C2779547634 @default.
• W4235302521 hasConcept C71924100 @default.
• W4235302521 hasConcept C72563966 @default.
• W4235302521 hasConcept C84393581 @default.
• W4235302521 hasConceptScore W4235302521C126322002 @default.
• W4235302521 hasConceptScore W4235302521C149323552 @default.
• W4235302521 hasConceptScore W4235302521C164705383 @default.
• W4235302521 hasConceptScore W4235302521C177713679 @default.
• W4235302521 hasConceptScore W4235302521C201903717 @default.
• W4235302521 hasConceptScore W4235302521C23131810 @default.
• W4235302521 hasConceptScore W4235302521C2776006263 @default.
• W4235302521 hasConceptScore W4235302521C2779547634 @default.
• W4235302521 hasConceptScore W4235302521C71924100 @default.
• W4235302521 hasConceptScore W4235302521C72563966 @default.
• W4235302521 hasConceptScore W4235302521C84393581 @default.
• W4235302521 hasIssue "10" @default.
• W4235302521 hasLocation W42353025211 @default.
• W4235302521 hasOpenAccess W4235302521 @default.
• W4235302521 hasPrimaryLocation W42353025211 @default.
• W4235302521 hasRelatedWork W2084665316 @default.
• W4235302521 hasRelatedWork W2106044895 @default.
• W4235302521 hasRelatedWork W2150620221 @default.
• W4235302521 hasRelatedWork W2366584003 @default.
• W4235302521 hasRelatedWork W2374865138 @default.
• W4235302521 hasRelatedWork W2379984495 @default.
• W4235302521 hasRelatedWork W3203444345 @default.
• W4235302521 hasRelatedWork W4206450723 @default.
• W4235302521 hasRelatedWork W4250185246 @default.
• W4235302521 hasRelatedWork W4250571922 @default.
• W4235302521 hasVolume "54" @default.
• W4235302521 isParatext "false" @default.
• W4235302521 isRetracted "false" @default.
• W4235302521 workType "article" @default.